Table 2

Summary of DLTs

Single-agent arm—no DLTs were reported
Combination arm
n (%)GWN323 10 mg+spartalizumab 100 mg q3wGWN323 10 mg+spartalizumab 200 mg q3wGWN323 30 mg+spartalizumab 100 mg q3wGWN323 30 mg+spartalizumab 300 mg q3wGWN323 75 mg+spartalizumab 300 mg q3wGWN323 150 mg+spartalizumab 300 mg q3wGWN323 300 mg+spartalizumab 300 mg q3wGWN323 750 mg+spartalizumab 300 mg q3wAll patients
N=6N=4N=4N=5N=4N=17N=7N=3N=50
All gradesGrade ≥3All gradesGrade ≥3All gradesGrade ≥3All gradesGrade ≥3All gradesGrade ≥3All gradesGrade ≥3All gradesGrade ≥3All gradesGrade ≥3All gradesGrade ≥3
Patients with ≥1 event001 (25.0)1 (25.0)1 (25.0)1 (25.0)00001 (5.9)1 (5.9)00003 (6.0)3 (6.0)
Blood creatine phosphokinase increased001 (25.0)1 (25.0)0000000000001 (2.0)1 (2.0)
Respiratory failure00001 (25.0)1 (25.0)00000000001 (2.0)1 (2.0)
Small intestinal obstruction00000000001 (5.9)1 (5.9)00001 (2.0)1 (2.0)
  • DLT, dose-limiting toxicity; q3w, every 3 weeks.